Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Pediatr Infect Dis J ; 42(12): e476-e478, 2023 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-37725819

RESUMEN

We analyzed multisystem inflammatory syndrome in children cases by reported COVID-19 vaccination status (2-dose primary series vs. no vaccination). A total of 46% vaccinated versus 58% unvaccinated persons received intensive care unit-level care ( P = 0.02); the risk of intensive care unit admission was 23% higher (adjusted relative risk: 1.23; 95% confidence interval: 1.03-1.48) among unvaccinated patients; 21 unvaccinated persons died. Multisystem inflammatory syndrome in children occurs after SARS-CoV-2 infection in vaccinated persons, but may be less severe.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Niño , Humanos , COVID-19/epidemiología , COVID-19/prevención & control , SARS-CoV-2 , Vacunación
2.
Pediatr Infect Dis J ; 42(4): e105-e108, 2023 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-36728676

RESUMEN

We describe characteristics, clinical features and outcomes of multisystem inflammatory syndrome in children among American Indian and Alaska Native (AI/AN) persons compared with non-Hispanic white persons. AI/AN patients with multisystem inflammatory syndrome in children were younger, more often obese, and from areas of higher social vulnerability. A greater proportion of AI/AN patients had severe respiratory involvement and shock.


Asunto(s)
Indio Americano o Nativo de Alaska , COVID-19 , Niño , Humanos , COVID-19/etnología , Estados Unidos/epidemiología
3.
MMWR Recomm Rep ; 71(4): 1-14, 2022 12 16.
Artículo en Inglés | MEDLINE | ID: mdl-36520808

RESUMEN

This report summarizes the evidence and rationale supporting the components of the CSTE/CDC MIS-C surveillance case definition and describes the methods used to develop the definition. These methods included convening MIS-C clinical experts (i.e., consultants): regarding identification of MIS-C and its distinction from other pediatric conditions, a review of available literature comparing MIS-C phenotype with that of pediatric COVID-19 and other hyperinflammatory syndromes, and retrospective application of different criteria to data from MIS-C cases previously reported to CDC.


Asunto(s)
COVID-19 , Estados Unidos/epidemiología , Humanos , COVID-19/diagnóstico , Epidemiólogos , Estudios Retrospectivos , SARS-CoV-2 , Centers for Disease Control and Prevention, U.S. , Vigilancia de la Población
4.
Clin Infect Dis ; 75(Suppl 2): S303-S307, 2022 10 03.
Artículo en Inglés | MEDLINE | ID: mdl-35684958

RESUMEN

We describe 2116 multisystem inflammatory syndrome in children (MIS-C) cases reported to the Centers for Disease Control and Prevention during Delta and Omicron circulation from July 2021 through January 2022. Half of MIS-C patients were aged 5-11 years, 52% received intensive care unit-level care, and 1.1% died. Only 3.0% of eligible patients were fully vaccinated prior to MIS-C onset.


Asunto(s)
COVID-19 , Enfermedades del Tejido Conjuntivo , Infecciones por Coronavirus , Neumonía Viral , COVID-19/complicaciones , Niño , Infecciones por Coronavirus/epidemiología , Humanos , Pandemias , Neumonía Viral/epidemiología , SARS-CoV-2 , Síndrome de Respuesta Inflamatoria Sistémica/epidemiología , Estados Unidos/epidemiología
6.
Clin Infect Dis ; 75(7): 1201-1209, 2022 09 30.
Artículo en Inglés | MEDLINE | ID: mdl-35100610

RESUMEN

BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is a novel severe postinfectious condition associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The purpose of this report is to describe nationwide trends in the evolving clinical management of MIS-C. METHODS: Patients with MIS-C were reported from state and local jurisdictions to the Centers for Disease Control and Prevention's (CDC's) MIS-C national surveillance system. Patients' case reports were reviewed to ensure that they met the CDC MIS-C case definition and had sufficient data for analysis. The prevalence of use of treatments for MIS-C, temporal trends in use of these treatments, and frequency of administration of different treatment combinations were analyzed. RESULTS: There were 4470 patients meeting the MIS-C case definition with onset dates from 19 February 2020 to 31 July 2021. The proportion of patients admitted to an intensive care unit (ICU) has declined over time, from 78.7% in April 2020 to 57.5% in June 2021 (P = .001). The most common treatments were intravenous immunoglobulin (IVIG), given to 85.6% of patients; steroids (77.7%), and antiplatelet medications (73.7%); use of each of these treatments has increased over time, particularly in patients not requiring admission to an ICU (all P < .001). Older patients and non-Hispanic Black patients were more likely to receive additional modes of therapy including vasoactive medication, noninvasive respiratory support, anticoagulation medication, and intubation/mechanical ventilation. CONCLUSIONS: IVIG, steroids, and antiplatelet medication have become increasingly utilized as standard treatment for MIS-C patients, while the use of other treatments may be contingent on the type and severity of clinical findings.


Asunto(s)
COVID-19 , Anticoagulantes , COVID-19/complicaciones , Niño , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , SARS-CoV-2 , Síndrome de Respuesta Inflamatoria Sistémica/tratamiento farmacológico , Síndrome de Respuesta Inflamatoria Sistémica/epidemiología , Estados Unidos/epidemiología
7.
Clin Infect Dis ; 75(1): e1165-e1175, 2022 08 24.
Artículo en Inglés | MEDLINE | ID: mdl-34864955

RESUMEN

BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is a severe hyperinflammatory condition in persons aged <21 years associated with antecedent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our objective was to describe MIS-C cases reported to Centers for Disease Control and Prevention's (CDC's) national surveillance since the coronavirus disease 2019 (COVID-19) pandemic began. METHODS: We included patients meeting the MIS-C case definition with onset date from 19 February 2020 through 31 July 2021, using CDC's MIS-C case report form, which collects information on demographics, clinical presentation, and laboratory results. Trends over time across 3 MIS-C pandemic waves were assessed using Cochran-Armitage test for categorical and Jonckheere-Terpstra test for continuous variables. RESULTS: Of 4901 reported cases, 4470 met inclusion criteria. Median patient age increased over time (P < .001), with a median of 9 years (interquartile range, 5-13 years) during the most recent (third) wave. Male predominance also increased (62% in third wave, P < .001). A significant (P < .001) increase in severe hematologic and gastrointestinal involvement was observed across the study period. Frequency of several cardiovascular complications (ie, cardiac dysfunction, myocarditis, and shock/vasopressor receipt) and renal failure declined (P < .001). Provision of critical care including mechanical ventilation (P < .001) and extracorporeal membrane oxygenation (ECMO; P = .046) decreased, as did duration of hospitalization and mortality (each P < .001). CONCLUSIONS: Over the first 3 pandemic waves of MIS-C in the United States, cardiovascular complications and clinical outcomes including length of hospitalization, receipt of ECMO, and death decreased over time. These data serve as a baseline for monitoring future trends associated with SARS-CoV-2 B.1.617.2 (Delta) or other variants and increased COVID-19 vaccination among children.


Asunto(s)
COVID-19 , Enfermedades del Tejido Conjuntivo , COVID-19/complicaciones , COVID-19/epidemiología , COVID-19/terapia , Vacunas contra la COVID-19 , Niño , Femenino , Humanos , Masculino , SARS-CoV-2 , Síndrome de Respuesta Inflamatoria Sistémica/epidemiología , Síndrome de Respuesta Inflamatoria Sistémica/terapia , Estados Unidos/epidemiología
8.
BMC Fam Pract ; 22(1): 177, 2021 09 07.
Artículo en Inglés | MEDLINE | ID: mdl-34488641

RESUMEN

BACKGROUND: Evidence on specific interventions to improve diabetes control in primary care is available, but this evidence is not always well-implemented. The concept of "mindlines" has been proposed to explain how clinicians integrate evidence using specifics of their practices and patients to produce knowledge-in-practice-in-context. The goal of this pilot study was to operationalize this concept by creating a venue for clinician-staff interaction concerning evidence. The research team attempted to hold "mindlines"-producing conversations in primary care practices about evidence to improve diabetes control. METHODS: Each of four primary care practices in a single health system held practice-wide conversations about a simple diabetes intervention model over a provided lunch. The conversations were relatively informal and encouraged participation from all. The research team recorded the conversations and took field notes. The team analyzed the data using a framework adapted from the "mindlines" research and noted additional emergent themes. RESULTS: While most of the conversation concerned barriers to implementation of the simple diabetes intervention model, there were examples of practices adopting and adapting the evidence to suit their own needs and context. Performance metrics regarding diabetes control for the four practices improved after the intervention. CONCLUSION: It appears that the type of conversations that "mindlines" research describes can be generated with facilitation around evidence, but further research is required to better understand the limitations and impact of this intervention.


Asunto(s)
Diabetes Mellitus , Atención Primaria de Salud , Diabetes Mellitus/prevención & control , Humanos , Conocimiento , Proyectos Piloto , Investigación Cualitativa
9.
Open Forum Infect Dis ; 8(8): ofab388, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-34409123

RESUMEN

Multisystem inflammatory syndrome in children (MIS-C) occurs among persons aged <21 years following severe acute respiratory syndrome coronavirus 2 infection. Among 2818 MIS-C cases, 35 (1.2%) deaths were reported, primarily affecting racial/ethnic minority persons. Being 16-20 years old or having comorbidities was associated with death. Targeting coronavirus disease 2019 prevention among these groups and their caregivers might prevent MIS-C-related deaths.

10.
MMWR Morb Mortal Wkly Rep ; 70(20): 733-738, 2021 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-34014907

RESUMEN

Outbreaks associated with treated recreational water can be caused by pathogens or chemicals in aquatic venues such as pools, hot tubs, water playgrounds, or other artificially constructed structures that are intended for recreational or therapeutic purposes. For the pseriod 2015-2019, public health officials from 36 states and the District of Columbia (DC) voluntarily reported 208 outbreaks associated with treated recreational water. Almost all (199; 96%) of the outbreaks were associated with public (nonbackyard) pools, hot tubs, or water playgrounds. These outbreaks resulted in at least 3,646 cases of illness, 286 hospitalizations, and 13 deaths. Among the 155 (75%) outbreaks with a confirmed infectious etiology, 76 (49%) were caused by Cryptosporidium (which causes cryptosporidiosis, a gastrointestinal illness) and 65 (42%) by Legionella (which causes Legionnaires' disease, a severe pneumonia, and Pontiac fever, a milder illness with flu-like symptoms). Cryptosporidium accounted for 2,492 (84%) of 2,953 cases resulting from the 155 outbreaks with a confirmed etiology. All 13 deaths occurred in persons affected by a Legionnaires' disease outbreak. Among the 208 outbreaks, 71 (34%) were associated with a hotel (i.e., hotel, motel, lodge, or inn) or a resort, and 107 (51%) started during June-August. Implementing recommendations in CDC's Model Aquatic Health Code (MAHC) (1) can help prevent outbreaks associated with treated recreational water in public aquatic venues.


Asunto(s)
Enfermedades Transmisibles/epidemiología , Brotes de Enfermedades/estadística & datos numéricos , Recreación , Purificación del Agua/estadística & datos numéricos , Baños/efectos adversos , Enfermedades Transmisibles/etiología , Cryptosporidium/aislamiento & purificación , Colonias de Salud/estadística & datos numéricos , Humanos , Legionella/aislamiento & purificación , Piscinas/estadística & datos numéricos , Estados Unidos/epidemiología , Microbiología del Agua
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA